These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37680472)

  • 1. A randomized clinical trial of bermekimab treatment for clinical improvement of systemic sclerosis.
    Solomonidi N; Vlachoyiannopoulos PG; Pappa M; Liantinioti G; Ktena S; Theotikos E; Elezoglou A; Netea MG; Giamarellos-Bourboulis EJ
    iScience; 2023 Sep; 26(9):107670. PubMed ID: 37680472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer.
    Kurzrock R; Hickish T; Wyrwicz L; Saunders M; Wu Q; Stecher M; Mohanty P; Dinarello CA; Simard J
    Oncoimmunology; 2019; 8(3):1551651. PubMed ID: 30723583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain.
    Gottlieb A; Natsis NE; Kerdel F; Forman S; Gonzalez E; Jimenez G; Hernandez L; Kaffenberger J; Guido G; Lucas K; Montes D; Gold M; Babcock C; Simard J
    J Invest Dermatol; 2020 Aug; 140(8):1538-1545.e2. PubMed ID: 32004568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Khanna D; Lin CJF; Furst DE; Goldin J; Kim G; Kuwana M; Allanore Y; Matucci-Cerinic M; Distler O; Shima Y; van Laar JM; Spotswood H; Wagner B; Siegel J; Jahreis A; Denton CP;
    Lancet Respir Med; 2020 Oct; 8(10):963-974. PubMed ID: 32866440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of serum interleukin(IL)-1α, IL-1β and IL-18 in patients with systemic sclerosis.
    Lin E; Vincent FB; Sahhar J; Ngian GS; Kandane-Rathnayake R; Mende R; Morand EF; Lang T; Harris J
    Clin Transl Immunology; 2019; 8(4):e1045. PubMed ID: 30997045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.
    Naidu GSRSNK; Sharma SK; Adarsh MB; Dhir V; Sinha A; Dhooria S; Jain S
    Rheumatol Int; 2020 Feb; 40(2):207-216. PubMed ID: 31813058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
    Schiopu E; Chatterjee S; Hsu V; Flor A; Cimbora D; Patra K; Yao W; Li J; Streicher K; McKeever K; White B; Katz E; Drappa J; Sweeny S; Herbst R
    Arthritis Res Ther; 2016 Jun; 18(1):131. PubMed ID: 27267753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
    Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
    Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial.
    Khanna D; Lin CJF; Furst DE; Wagner B; Zucchetto M; Raghu G; Martinez FJ; Goldin J; Siegel J; Denton CP
    Am J Respir Crit Care Med; 2022 Mar; 205(6):674-684. PubMed ID: 34851799
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).
    Khanna D; Denton CP; Lin CJF; van Laar JM; Frech TM; Anderson ME; Baron M; Chung L; Fierlbeck G; Lakshminarayanan S; Allanore Y; Pope JE; Riemekasten G; Steen V; Müller-Ladner U; Spotswood H; Burke L; Siegel J; Jahreis A; Furst DE
    Ann Rheum Dis; 2018 Feb; 77(2):212-220. PubMed ID: 29066464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis.
    Distler O; Pope J; Denton C; Allanore Y; Matucci-Cerinic M; de Oliveira Pena J; Khanna D
    Respir Med; 2017 Jan; 122 Suppl 1():S14-S17. PubMed ID: 27746061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma.
    Gong J; Thomassian S; Kim S; Gresham G; Moshayedi N; Ye JY; Yang JC; Jacobs JP; Lo S; Nissen N; Gaddam S; Tighiouart M; Osipov A; Hendifar A
    Sci Rep; 2022 Sep; 12(1):15013. PubMed ID: 36056179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics.
    Ebata S; Yoshizaki-Ogawa A; Sato S; Yoshizaki A
    J Clin Med; 2022 Aug; 11(15):. PubMed ID: 35956246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis.
    Denton CP; Del Galdo F; Khanna D; Vonk MC; Chung L; Johnson SR; Varga J; Furst DE; Temple J; Zecchin C; Csomor E; Lee A; Wisniacki N; Flint SM; Reid J
    Rheumatology (Oxford); 2022 Dec; 62(1):234-242. PubMed ID: 35583273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).
    Distler O; Brown KK; Distler JHW; Assassi S; Maher TM; Cottin V; Varga J; Coeck C; Gahlemann M; Sauter W; Schmidt H; Highland KB;
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):75-81. PubMed ID: 28664834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial.
    Mantero JC; Kishore N; Ziemek J; Stifano G; Zammitti C; Khanna D; Gordon JK; Spiera R; Zhang Y; Simms RW; Lafyatis R
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):146-149. PubMed ID: 30277862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A.
    Kawaguchi Y; Hara M; Wright TM
    J Clin Invest; 1999 May; 103(9):1253-60. PubMed ID: 10225968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum C-X-C Chemokine Ligand 1 Levels in Patients with Systemic Sclerosis: Relationship of Clinical and Laboratory Observations to Anti-CD20 Monoclonal Antibody Administration.
    Kawanabe R; Yoshizaki A; Matsuda KM; Kotani H; Hisamoto T; Norimatsu Y; Kuzumi A; Fukasawa T; Ebata S; Yoshizaki-Ogawa A; Sato S
    Life (Basel); 2022 Apr; 12(5):. PubMed ID: 35629314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.